Steve Gillis
Chairman
Biomedical Sciences
Lycera
United States of America
Biography
Dr. Steven Gillis is a managing director with ARCH Venture Partners, joining the firm in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of Accelerator, Allozyne, Variation Biotechnologies, Surface Logix, PhaseRx, Pulmatrix and Qwell Pharmaceuticals. He serves as director and chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST. As a former director and chairman of Trubion Pharmaceuticals (TRBN), he led its acquisition by Emergent BioSolutions in early 2010.
Research Interest
Biomedical Systems & Emerging Technologies Biomolecular Research & Therapeutics
